ICD Placement and Medical Therapy in ARVD
An ICD should be implanted in all ARVD patients with documented cardiac arrest or sustained ventricular tachycardia, and should be strongly considered for those with syncope, extensive disease, or high-risk features even without prior sustained arrhythmias.
Secondary Prevention (Strongest Indication)
ICD implantation is the definitive treatment for ARVD patients who have survived cardiac arrest or experienced sustained VT. 1, 2 This represents a Class I recommendation with Level B evidence across multiple international guidelines. 1, 2
- Patients with hemodynamically unstable VT or VT with syncope require ICD placement if they have reasonable expectation of survival >1 year with good functional status. 2
- The efficacy of antiarrhythmic drugs in ARVD is low and difficult to predict, making ICD the preferred strategy over medical therapy alone. 3
Primary Prevention (More Nuanced)
High-Risk Features Warranting ICD Consideration
ICD implantation is reasonable (Class IIa) for primary prevention in ARVD patients with:
- Extensive disease with left ventricular involvement 2
- One or more family members with sudden cardiac death 2
- Unexplained syncope when VT/VF has not been excluded 1, 2
- Severe right ventricular dysfunction 4
- Age <40 years at time of consideration 4
Risk Stratification Evidence
The most recent high-quality observational data demonstrates that 24% of ARVD patients without prior sustained VT/VF who received ICDs for risk factors had appropriate ICD interventions over 58 months of follow-up, with 16% receiving shocks for life-threatening VF/ventricular flutter. 5
Critical predictors of appropriate ICD therapy include:
- Syncope (hazard ratio 2.94-3.16 for appropriate interventions and VF/flutter) 5, 4
- Right ventricular dysfunction (cause-specific HR 2.85) 4
- Age <40 years (cause-specific HR 2.37) 4
- History of sustained VT (cause-specific HR 2.55) 4
Important Caveats
Asymptomatic patients with isolated family history of sudden death may not require prophylactic ICD. None of the 27 asymptomatic patients with only familial sudden death in one registry study had appropriate ICD therapy during follow-up. 5
Electrophysiologic testing has limited predictive value - positive predictive value of only 35% for any appropriate ICD intervention and 20% for VF/flutter shocks, with negative predictive value of 70% and 74%. 5 EP testing may be considered (Class IIb) but should not be the sole determinant. 2
Medical Therapy Recommendations
Antiarrhythmic Drugs
First-line medical therapy in ARVD is antiarrhythmic drugs, particularly for monomorphic VT. 3
- Amiodarone or sotalol can be effective for sustained VT/VF when ICD is not feasible (Class IIa). 2
- Amiodarone should be considered in ICD patients experiencing recurrent appropriate shocks despite optimal device programming. 6
- Beta-blockers are recommended for all ARVD patients to reduce arrhythmic burden. 7, 8
- Antiarrhythmic drugs should not replace ICD therapy but may be used adjunctively. 1
Additional Medical Management
- ACE inhibitors/ARBs and beta-blockers should be initiated to limit structural progression and prevent ventricular arrhythmias. 7
- Sodium channel blockers and dronedarone are not recommended in cardiomyopathy patients. 6
Catheter Ablation
Catheter ablation is recommended for bundle branch reentrant VT (Class I) and should be considered as adjunctive therapy for recurrent VT despite optimal antiarrhythmic therapy (Class IIa). 2, 6
- Epicardial ablation may be necessary if endocardial ablation fails. 7
- Ablation does not replace ICD need due to high recurrence rates. 6
Lifestyle Modifications
All ARVD patients should avoid strenuous or high-intensity sports activities (Class I, Level B). 1 Patients should discontinue competitive athletics entirely. 7, 8
Device-Related Complications
Be aware that inappropriate ICD shocks occur in 19-28% of ARVD patients, with oversensing of myopotentials and cardiac signals being the most common causes. 9, 5 Device-related complications occur in approximately 17% of patients. 5
Contraindications
ICD implantation is not recommended in patients with terminal illness with life expectancy <6 months, severe psychiatric illness, or NYHA Class IV heart failure without transplant candidacy. 3